Literature DB >> 16830652

Persister studies in leprosy patients after multi-drug treatment.

U D Gupta1, K Katoch, H B Singh, M Natrajan, V M Katoch.   

Abstract

Cutaneous biopsies were collected from leprosy patients who attended the out-patient department of the Institute for treatment at different intervals, i.e., 12 months, 18 months, 24 months, 36 months, and more after beginning the multi-drug treatment therapy (M.D.T.). The patients belonged to the two drug regimens; (i) standard multibacillary (MB) M.D.T. after 12, 24, and 36 months; or (ii) standard M.D.T. + Minocycline 100 mg once a month (supervised) + Ofloxacin 400 mg once a month supervised for 12 months Biopsies were processed for mouse footpad inoculation and for estimating ATP levels by bioluminescence assay as per established methods. Viable bacilli were observed in 23.5% up to 1 year, 7.1% at 2 years, and in 3.84% at 3 years of M.D.T. by MFP and 29.4%, 10.7%, and 3.84% by ATP assay in the M.D.T. group at the same time period, respectively, but not in M.D.T. + Minocycline + Ofloxacin group after one year. The overall percentage of persisters was 5.55% by MFP and 7.14% by ATP assay up to 3 years of treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16830652

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  4 in total

1.  Alternate Anti-Leprosy Regimen for Multidrug Therapy Refractory Leprosy: A Retrospective Study from a Tertiary Care Center in North India.

Authors:  Tarun Narang; Anuradha Bishnoi; Sunil Dogra; Uma Nahar Saikia
Journal:  Am J Trop Med Hyg       Date:  2019-01       Impact factor: 2.345

2.  Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal.

Authors:  Saraswoti Khadge; Sayera Banu; Kidist Bobosha; Jolien J van der Ploeg-van Schip; Isabela M Goulart; Pratibha Thapa; Chhatra B Kunwar; Krista E van Meijgaarden; Susan J F van den Eeden; Louis Wilson; Senjuti Kabir; Hymonti Dey; Luiz R Goulart; Janaina Lobato; Washington Carvalho; Yonas Bekele; Kees L M C Franken; Abraham Aseffa; John S Spencer; Linda Oskam; Tom H M Otttenhoff; Deanna A Hagge; Annemieke Geluk
Journal:  BMC Infect Dis       Date:  2015-10-28       Impact factor: 3.090

3.  Drug Resistance in Mycobacterium Leprae in the Context of Zero Leprosy.

Authors:  Itu Singh; Utpal Sengupta
Journal:  Indian Dermatol Online J       Date:  2021-11-22

4.  Genomic Reduction at TTC Repeats in the Bacterial Genome of Treated Cases of Hansen's Disease: A Possible Survival Mechanism of Mycobacterium leprae.

Authors:  Abu Hena Hasanoor Reja; Abhishek De; Pradip Kumar Patra; Supratik Biswas; Umesh Duttagupta; Amrita Sil; Nibir Biswas; Surajita Bannerjee; Aarti Sarda; Basudev Bhattacharya
Journal:  Indian J Dermatol       Date:  2018 Nov-Dec       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.